A Study of Guselkumab in Participants With Active Psoriatic Arthritis

第3相実施中（募集終了） NCT04882098

対象疾患	Arthritis, Psoriatic
相	第3相
スポンサー	Janssen Research & Development, LLC
ステータス	実施中（募集終了）
参加者数	1,054 名
介入（薬剤）	Guselkumab
開始日	2021年6月17日
完了日	2024年12月30日
結果公開日	2026年2月4日

概要

The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) by assessing the reduction in signs and symptoms of PsA.

Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 24

At Week 24 · percentage of participants

Group 1: Guselkumab 100 mg q8w	68.3 percentage of participants
Group 2: Guselkumab 100 mg q4w	66.6 percentage of participants
Group 3: Placebo Followed by Guselkumab	47.0 percentage of participants

p-value	<0.001
Difference in percentage	21.3 (95% CI 14.4–28.2)

BENITIONS で見る ClinicalTrials.gov の原文を見る

同じ疾患の他の治験

A Study to Assess the Pharmacokinetics, Safety, and Efficacy of Two Doses of Bimekizumab i — UCB Biopharma SRL
A Study of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoria — Janssen Pharmaceutical K.K.
A Study of Guselkumab and Golimumab Combination Therapy in Participants With Active Psoria — Janssen Research & Development, LLC
A Study to Evaluate the Efficacy and Safety of Bimekizumab in the Treatment of Subjects Wi — UCB Biopharma SRL
A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With A — UCB Biopharma SRL
The Efficacy and Safety of TLL018 in Moderate-to-severe Plaque Psoriasis — Hangzhou Highlightll Pharmaceutical Co., Ltd

すべての治験

このページは ClinicalTrials.gov の公開データをまとめたものです。医学的助言ではなく、投資助言でもありません。必ず専門医にご相談ください。

English 한국어 日本語中文 Русский